R
Roisin M. Connolly
Researcher at Johns Hopkins University
Publications - 94
Citations - 3736
Roisin M. Connolly is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 24, co-authored 79 publications receiving 2816 citations. Previous affiliations of Roisin M. Connolly include Johns Hopkins University School of Medicine & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Beta Blockers and Breast Cancer Mortality: A Population- Based Study
Thomas I. Barron,Roisin M. Connolly,Roisin M. Connolly,Linda Sharp,Linda Sharp,Kathleen Bennett,Kathleen Bennett,Kala Visvanathan +7 more
TL;DR: Evidence in humans is provided to support preclinical observations suggesting that inhibiting the β₂-adrenergic signaling pathway can reduce breast cancer progression and mortality.
Journal ArticleDOI
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers.
Huili Li,Katherine B. Chiappinelli,Angela A. Guzzetta,Hariharan Easwaran,Ray Whay Chiu Yen,Rajita Vatapalli,Michael J. Topper,Jianjun Luo,Roisin M. Connolly,Nilofer S. Azad,Vered Stearns,Drew M. Pardoll,Nancy E. Davidson,Peter A. Jones,Dennis J. Slamon,Stephen B. Baylin,Cynthia A. Zahnow,Nita Ahuja +17 more
TL;DR: Results point to a broad immune stimulatory role for DNA demethylating drugs in multiple cancers, particularly in breast and colorectal cancers.
Journal ArticleDOI
Early discontinuation of tamoxifen: a lesson for oncologists.
TL;DR: The purpose of the study was to assess rates of tamoxifen nonpersistence (early discontinuation) in women aged 35 years or older using prescription refill data from a national prescribing database.
Journal ArticleDOI
TBCRC 022: A phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases
Rachel A. Freedman,Rebecca Gelman,Carey K. Anders,Michelle E. Melisko,Heather A. Parsons,Anne Cropp,Kelly Silvestri,Christine M Cotter,Kathryn P. Componeschi,Juan M. Marte,Roisin M. Connolly,Beverly Moy,Catherine Van Poznak,Kimberly L. Blackwell,Shannon Puhalla,Rachel C. Jankowitz,Karen L. Smith,Nuhad K. Ibrahim,Timothy J. Moynihan,Ciara C. O’Sullivan,Julie R. Nangia,Polly A. Niravath,Nadine Tung,Paula R. Pohlmann,Robyn Burns,Mothaffar F. Rimawi,Ian E. Krop,Antonio C. Wolff,Eric P. Winer,Nan Lin +29 more
TL;DR: Neratinib plus capecitabine is active against refractory, Her2-positive breast cancer brain metastases, adding additional evidence that the efficacy of HER2-directed therapy in the brain is enhanced by chemotherapy.
Journal ArticleDOI
Treatment of HER2-positive breast cancer
TL;DR: The current data on the therapeutic management of HER2-positive breast cancer is reviewed, and recent guidance by the US Food and Drug Administration suggests that pathologic response to Her2-targeted therapy given preoperatively may allow an earlier assessment of their clinical benefit in the adjuvant setting.